AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28326559
Drug: RG7652 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 (40 or 150 mg multiple doses once weekly for 4 weeks)
Trial: 28326559
Drug: RG7652 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 with atorvastatin
Trial: 26490026
Drug: Concurrent chemo-endocrine
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-endocrine therapy (goserelin for premenopausal women or an aromatase inhibitor for postmenopausal women)
Trial: 26490026
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide)
Trial: 23266743
Drug: 6 tablets
RxNorm normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Trial: 23266743
Drug: 3 tablets
RxNorm normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Trial: 23266743
Drug: 6 tablets
RxNorm normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets of dietary supplement (DS)
Trial: 23266743
Drug: 3 tablets
RxNorm normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of dietary supplement (DS)
Trial: 23266743
Drug: 6 tablets
RxNorm normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets of dietary supplement (DS) and 3 tablets of dietary supplement (DS)
Trial: 17428714
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (40 or 80 mg)
Trial: 10683600
Drug: SPORT (dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPORT (dietary supplement)
Trial: 9587555
Drug: 18 patients
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 patients who had a second biopsy 6 months after therapy
Trial: 8410127
Drug: 4HPR 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4HPR 200 mg/d for 5 years
Trial: 30776254
Drug: Taurine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (50 mg kg‐1)
Trial: 30268158
Drug: Low-frequency electrostimulation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency electrostimulation (ES) administered via CarebandR wristband on unilateral PC6 acupoint
Trial: 26672608
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg elemental iron once weekly (Group-A)
Trial: 26672608
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg elemental iron twice weekly (Group-B)
Trial: 22890091
Drug: Prulifloxacin 264.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 264.2 mg b.i.d. for 5-14 days
Trial: 22890091
Drug: Levofloxacin 200
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 200 mg b.i.d. for 5-14 days
Trial: 18946341
Drug: Concentration-controlled MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration-controlled MMF regimen (target exposure 45 mg hr/L)
Trial: 18946341
Drug: Fixed-dose MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose MMF regimen
Trial: 16054584
Drug: Amodiaquine +
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine + Artesunate (ADQ+ART) combination
Trial: 16054584
Drug: Artemether +
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether + Lumefantrine (Coartem) combination
Trial: 12468602
Drug: Spread enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread enriched with plant sterol-esters (12 g/100 g plant sterols), intake of 15 g/d
Trial: 10522000
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily before breakfast
Trial: 10522000
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once daily at bedtime
Trial: 1826987
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (600 mg ascorbic acid, 300 mg alpha‐tocopherol, 27 mg beta‐carotene, and 75 micrograms selenium in yeast daily)
Trial: 30685675
Drug: Evolocumab (proprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (proprotein convertase subtilisin‐kexin type 9 inhibitor)
Trial: 21893649
Drug: Daily controller
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily controller use (yes)
Trial: 21893649
Drug: Leukotriene inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene inhibitors (yes)
Trial: 21893649
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (yes)
Trial: 15235319
Drug: DCA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCA (50 mg·kg‐1 body mass in 50 mL saline)
Trial: 11238496
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, 3 times daily for 4 weeks)
Trial: 11238496
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily for 4 weeks)
Trial: 9928576
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment A(doxorubicin)-T(paclitaxel)-C(cyclophosphamide) with G-CSF
Trial: 9928576
Drug: AC x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC x 4 followed by high-dose chemotherapy with stem cell support
Trial: 31204870
Drug: Self-administered anonymous
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered anonymous questionnaire regarding fertility management knowledge
Trial: 27959700
Drug: Platinum therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum therapy plus pemetrexed (500 mg/m² + carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks)
Trial: 27959700
Drug: Platinum therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum therapy plus pemetrexed
Trial: 26041765
Drug: Comfort level
RxNorm normalized name: Comfort Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfort level with prescribing treatment to ECOG 4 patients
Trial: 21494196
Drug: Real electroacupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real electroacupuncture treatment
Trial: 21494196
Drug: Simulated electroacupuncture
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated electroacupuncture treatment (Control)
Trial: 19688181
Drug: Tacrolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (3 mg/day)
Trial: 15356433
Drug: Daily needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily needle aspiration
Trial: 9133750
Drug: Active treatments
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatments (Imipramine)
Trial: 27083332
Drug: Ponatinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (45 mg once daily)
Trial: 27083332
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg once daily)
Trial: 14760148
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg salbutamol administered through a pMDI+spacer 20 minutes before induction
Trial: 14760148
Drug: 1500 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 microg nebulised salbutamol inhaled throughout the induction procedure
Trial: 7583013
Drug: Garlic capsules
RxNorm normalized name: Garlic 500 MG Oral Capsule, Liquid Filled [GARLIC CAPSULES]
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic capsules
Trial: 2378856
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol maleate (0.5%)
Trial: 2378856
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol hydrochloride (0.5%)
Trial: 387069
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of micronized 17 beta‐oestradiol and 3 mg norethisterone (Netagen 403)
Trial: 387069
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg 17 beta‐oestradiol plus 2 mg of oestriol and 3 mg norethisterone (Netagen 423)
Trial: 387069
Drug: 50 microgram
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microgram ethinyl oestradiol and 3 mg norethisterone (Netasyn)
Trial: 24147745
Drug: gel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gel without desensitizing agent (n=17)
Trial: 24147745
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 2% sodium fluoride (n=17)
Trial: 24147745
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 10% CPP‐ACP (n=17)
Trial: 22336530
Drug: Conventional antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antimicrobial treatment (non-de-escalation, NDE)
Trial: 19047297
Drug: Adjuvant goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant goserelin after radiation therapy (RT)
Trial: 11408151
Drug: Loperamide-simethicone combination
RxNorm normalized name: loperamide / simethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide-simethicone combination formulation
Trial: 2163253
Drug: Soy cotyledon
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy cotyledon fiber supplementation (15 grams per day in three divided doses)
Trial: 892352
Drug: Salt and
RxNorm normalized name: ZINC OXIDE 240 mg in 1 g TOPICAL STICK [Salt and Stone Outdoor Voices SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt and water restriction plus diuretics
Trial: 30829779
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum (CCH) 0.84 mg
Trial: 24861902
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral caffeine intake
Trial: 23237127
Drug: Attention-control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-control group (supportive therapy)
Trial: 15516290
Drug: 25 microg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg/h F transdermal patches (N = 142)
Trial: 15516290
Drug: 50 microg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/h F transdermal patches (N = 184)
Trial: 15516290
Drug: 75 microg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg/h F transdermal patches (N = 85)
Trial: 15516290
Drug: 100 microg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/h F transdermal patches (N = 135)
Trial: 9722255
Drug: Systemic and
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic and inhaled saline
Trial: 3058630
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of steroids (32 mg of oral methylprednisolone, approximately 2 hours before CM challenge)
Trial: 3058630
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of steroids (32 mg approximately 12 hours and 2 hours before CM challenge)
Trial: 22124795
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Cu/d (supplemented group, SG)
Trial: 19561530
Drug: mesalazine scheduled
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mesalazine scheduled daily
Trial: 12192167
Drug: DTPa-HepB combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HepB combination vaccine
Trial: 12192167
Drug: Monovalent HepB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent HepB vaccine
Trial: 9655370
Drug: DHA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA group (7 subjects) - 6 g DHA/d for 90 days after a basal diet for 30 days
Trial: 2592587
Drug: Velnacrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine (100 mg) administered after an overnight fast
Trial: 2592587
Drug: Velnacrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine (100 mg) administered 15 minutes after a standard breakfast
Trial: 22936319
Drug: Synchronized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronized therapy group (I-125 seeds implantation combined with chemotherapy and Chinese medicine)
Trial: 22936319
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus CM-treated group
Trial: 22936319
Drug: Chemotherapy-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-treated group
Trial: 18926641
Drug: Monoamine reuptake
RxNorm normalized name: Non-selective monoamine reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine reuptake inhibitors
Trial: 17632217
Drug: Quetiapine, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine, 400 mg/d at bedtime
Trial: 14767152
Drug: Multimodal cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cognitive-behavioral therapy (CBT)
Trial: 11396366
Drug: Dose-dense, dose-intense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense, dose-intense EC‐>T (epirubicin, cyclophosphamide, followed by paclitaxel)
Trial: 2826098
Drug: Raw wheat
RxNorm normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw wheat whole-meal preparation
Trial: 2826098
Drug: Heated wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated wheat and corn whole-meal preparations
Trial: 31915255
Drug: Tiagabine (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (oral, 10 mg)
Trial: 28348720
Drug: EMDR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR therapy carried out by a psychologist
Trial: 23903476
Drug: Topical 0.03%
RxNorm normalized name: tacrolimus topical 0.03% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.03% budesonide rinse
Trial: 23903476
Drug: Topical 0.01%
RxNorm normalized name: tretinoin topical 0.01% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.01% dexamethasone rinse
Trial: 21098871
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 3 months
Trial: 8334888
Drug: Triphasic combined
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic combined oral contraceptive
Trial: 8334888
Drug: Low-dose monophasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monophasic combined oral contraceptive
Trial: 24621680
Drug: N-acetylcysteine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg twice daily
Trial: 20642691
Drug: EPO-beta (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO-beta (30,000 UI each) administered before surgery and at 12 h, 7 days, and 14 days posttransplantation.
Trial: 20642691
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EPO-beta treatment).
Trial: 15918388
Drug: i.v. remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. remifentanil PCA (loading dose: 45 microg, maintenance dose: 1 microg min(‐1), bolus dose: 15 microg, lockout interval: 10 min)
Trial: 15918388
Drug: i.v. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. morphine PCA (loading dose: 5 mg, maintenance dose: 0.3 mg h(‐1), bolus dose: 1 mg, lockout interval: 15 min)
Trial: 11448655
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg + sulfonylurea
Trial: 11448655
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg + sulfonylurea
Trial: 465179
Drug: Cholestyramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine plus usual treatment (rehydration, refeeding, furazolidone)
Trial: 465179
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (rehydration, refeeding, furazolidone)
Trial: 28809658
Drug: Cognitive-Functional (Cog-Fun)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Functional (Cog-Fun) occupational therapy intervention
Trial: 17151159
Drug: Switching antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching antipsychotics
Trial: 19725969
Drug: Initial antipsychotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antipsychotic therapy
Trial: 17563126
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg plus paracetamol 500 mg
Trial: 11403726
Drug: Baclofen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (20 mg)
Trial: 9951580
Drug: Chemotherapy including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy including doxorubicin and/or cyclophosphamide
Trial: 9951580
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without doxorubicin and/or cyclophosphamide
Trial: 17617528
Drug: Single-agent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent cisplatin
Trial: 8091240
Drug: Platinum-based multiagent
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based multiagent chemotherapy
Trial: 3292601
Drug: Superactivated charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superactivated charcoal (20 g twice daily)
Trial: 30912806
Drug: Combined GH/GnRHa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined GH/GnRHa therapy
Trial: 30912806
Drug: Prepubertal status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepubertal status at onset of GH treatment
Trial: 28830024
Drug: Cognitive exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive exercise therapy (CET) in addition to cognitive-behavioral therapy (CBT) and graded exercise therapy (GET)
Trial: 28830024
Drug: Cognitive exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive exercise therapy (CET)
Trial: 28830024
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and graded exercise therapy (GET) alone
Trial: 25638341
Drug: Individualized hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized hormone adjustment (estrogen, progesterone, and luteinizing hormones)
Trial: 21522037
Drug: Motavizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motavizumab (15 mg/kg, five monthly doses)
Trial: 21522037
Drug: Palivizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab (15 mg/kg, five monthly doses)
Trial: 19883270
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g glucose (placebo)
Trial: 16534469
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (no therapy)
Trial: 7528560
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime) (N = 20)